Dutatoz 0.5mg Tablet

Overview Dutatoz 0.5mg Tablet

Benign prostatic hyperplasia (BPH) is treated with Dutatoz 0.5mg tablets, which reduce prostate size, alleviating urinary discomfort and pain. Administered orally, with or without food, this medication requires long-term use (several months) for noticeable improvement. Complete the prescribed course as directed by your physician. While generally well-tolerated, minor sexual side effects, including reduced libido, are possible. Post-treatment, blood donation should be deferred for six months.

Uses of Dutatoz 0.5mg Tablet

Noncancerous prostate gland enlargement

Major Benefits of Dutatoz 0.5mg Tablet:

Administer this medication precisely as prescribed by your physician, adhering to both dosage and treatment length. Ingest the 0.5mg Dutatoz tablet whole; avoid chewing, crushing, or fracturing it. Consumption with or without food is acceptable, though consistent timing is recommended.

Common Side effects of Dutatoz 0.5mg Tablet:

• Decreased libido
• Ejaculation disorder
• Breast enlargement in male
• Breast tenderness in male
• Impotence
• Decreased sperm count

How to use Dutatoz 0.5mg Tablet:

Administer this medication precisely as prescribed by your physician, adhering to both the dosage and treatment duration. Ingest the 0.5mg Dutatoz tablet whole; avoid chewing, crushing, or fracturing it. Consumption may coincide with meals or be taken independently, although consistent timing is recommended.

How Dutatoz 0.5mg Tablet works:

Dutatoz 0.5mg tablets contain a 5-alpha reductase inhibitor. This medication works by suppressing an enzyme crucial for converting testosterone into a hormone that promotes prostate enlargement. Consequently, it reduces prostate size and alleviates symptoms such as urinary hesitancy.

What if you forget to take Dutatoz 0.5mg Tablet :

Should you forget a Dutatoz 0.5mg Tablet dose, administer it promptly. Nevertheless, if your next dose is imminent, omit the missed dose and resume your usual dosing regimen. Avoid taking a double dose.